Response to Media Comment

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Feb 03, 2003

GW notes recent media comments relating to its commercialisation discussions. The Company has consistently stated its commercial strategy to be to enter into partnerships following Phase III trial results in order to secure optimum commercial terms.

GW notes recent media comments relating to its commercialisation discussions.

The Company has consistently stated its commercial strategy to be to enter into partnerships following Phase III trial results in order to secure optimum commercial terms. In its preliminary results statement of 15 January 2003, GW announced that, having reported positive results from four Phase III trials, the Company is presently in active discussions with a number of pharmaceutical companies regarding the commercialisation of its range of products.

These discussions are continuing as planned and there have been no events since the Company’s recent announcements which alter the target timescales for concluding GW’s first commercial partnership arrangement. GW remains on track to sign its first commercial arrangements during the first half of 2003, as indicated throughout last year and in the Company’s recent preliminary results statement.

The Company is scheduled to submit its regulatory application to the Medicines Control Agency during the first quarter of 2003. Subject to regulatory approval, GW aims to launch its first product in the UK towards the end of 2003.

- Ends -

GW Pharmaceuticals plc  
01980 557000
Justin Gover, Managing Director  

Weber Shandwick Square Mile  
020 7067 0700
Kevin Smith/Graham Herring

Recent News